Cannabis Use DisorderNCT05522205
Regulated Cannabis Access in Basel
A study testing Regulated cannabis access in pharmacies in people with Cannabis Use Disorder and Mental Health Disorder, run by Health Department of the Canton of Basel-Stadt at 1 site in Switzerland.
Trial summary
The randomised controlled study on regulated cannabis access in pharmacies in Basel aims to investigate the effects of regulated cannabis access on consumption behaviour and mental and physical health in comparison to the illegal market. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Cannabis Use Disorder, Mental Health Disorder, Physical Illness
- What is being tested?
- Regulated cannabis access in pharmacies
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 374 participants
- Where
- 1 siteSwitzerland
- Study dates
- 31 Jan 2023to 31 Jan 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- At least 18 years, residence in Basel-Stadt, consuming cannabis at least monthly during the last 6 months (positive urine sample)
Who cannot join
- pregnant or breastfeeding, currently suicidal, currently psychotic, current inpatient psychiatric treatment
Trial locations and contacts
1 site in 1 country.
About this study
Official title: WEED CARE - Randomized Controlled Study on Regulated Cannabis Access for Recreational Use in Pharmacies in Basel
The randomised controlled study on regulated cannabis access in pharmacies in Basel aims to investigate the effects of regulated cannabis access on consumption behaviour and mental and physical health in comparison to the illegal market.
Read the detailed description
This project consist of two parts: The first part is a randomised controlled study, the second part is an observational study. The randomised controlled study will last six months. Participants will randomly be assigned to one of two groups: Group 1 has immediately access to regulated cannabis in pharmacies; Group 2 has to wait for six months. After six months all participants will have access to regulated cannabis in pharmacies (oberservational study). Every six month participants will be invited to answer online-questionnaires on their cannabis consumption behavior, their mental and physical health. The entire study lasts 2.5 years.
- Being tested
- Regulated cannabis access in pharmacies
- Keywords
- cannabis regulation, health effects, cannabis consumption
- Medical subject headings
- Mental Disorders
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Regulated cannabis access in pharmaciesOther
The study does not investigate the health effects of cannabis. The study investigates the effects of regulated cannabis access on cannabis consumption and health in comparison to the unregulated illegal market.
| Study group | Role | What they receive |
|---|---|---|
| Experimental group | Experimental | Immediately regulated cannabis access in pharmacies. Receives: Other: Regulated cannabis access in pharmacies |
| Control group | No intervention | During the first six months participants of the control group have to continue to buy their cannabis on the illicit market. Afterthese six months they also have access to regulated cannabis access. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in problematic cannabis consumption behaviour
Cannabis Use Disorder Identification Test - Revised; min. value 0, max. value 32; higher scores mean worse outcome
Measured: 6 / 12 /18 /24 / 30 months
Secondary outcomes (4)
Change in depression
Patient Health Questionnaire; min. value 0, max. value 27; higher scores mean worse outcome
Measured: 6 / 12 /18 /24 / 30 months
Change in anxiety
Generalized Anxiety Disorder; min. value 0, max. value 21; higher scores mean worse outcome
Measured: 6 / 12 /18 /24 / 30months
Change in psychosis
Checklist of early intervention; min. value 0, max. value 8; higher scores mean worse outcome
Measured: 6 / 12 /18 /24 / 30 months
Change in physical health
Symptom Checklist - 90, Somatization; min. value 0, max. value 48; higher scores mean worse outcome
Measured: 6 / 12 /18 /24 / 30 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 Aug 2022
- Study start31 Jan 2023
- Primary completion31 Jan 2027 (estimated)
- Study completion31 Jan 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Cannabis Use DisorderStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 374 participants (actual)
Sponsor and investigators
- Lead sponsor
- Health Department of the Canton of Basel-Stadt
- Sponsor type
- Other government
- Collaborators
- University of Basel, University Psychiatric Clinics Basel, Psychiatric Services Aargau AG
- Responsible party
- Principal investigator, Marc Walter, Psychiatric Services Aargau AG
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05522205
- Sponsor's protocol ID
- 2021-01670
- Status last verified
- Sep 2026
- First submitted
- 8 Aug 2022
- Last updated
- 2 Sep 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: All IPD that underlie results in publications.
Publications
Baltes-Flueckiger L, Steinauer R, Meyer M, Vogel M, Walter M. Effects of cannabis regulation in Switzerland: Study protocol of a randomized controlled trial. Front Psychiatry. 2023 Mar 23;14:1139325. doi: 10.3389/fpsyt.2023.1139325. eCollection 2023.
PubMed 37032954
Study at a glance
From the registry record, last updated by the sponsor on 2 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- WEED CARE - Randomized Controlled Study on Regulated Cannabis Access for Recreational Use in Pharmacies in Basel
- ClinicalTrials.gov ID
- NCT05522205
- Acronym / sponsor ID
- 2021-01670
- Keywords
- cannabis regulation, health effects, cannabis consumption
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 374 participants (actual)
- Lead sponsor
- Health Department of the Canton of Basel-StadtOther government
- Collaborators
- University of Basel, University Psychiatric Clinics Basel, Psychiatric Services Aargau AG
- Study start
- 31 Jan 2023 (actual)
- Primary completion
- 31 Jan 2027 (estimated)
- Study completion
- 31 Jan 2027 (estimated)
- First posted
- 30 Aug 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The randomised controlled study on regulated cannabis access in pharmacies in Basel aims to investigate the effects of regulated cannabis access on consumption behaviour and mental and physical health in comparison to the illegal market.
Detailed description
This project consist of two parts: The first part is a randomised controlled study, the second part is an observational study. The randomised controlled study will last six months. Participants will randomly be assigned to one of two groups: Group 1 has immediately access to regulated cannabis in pharmacies; Group 2 has to wait for six months. After six months all participants will have access to regulated cannabis in pharmacies (oberservational study). Every six month participants will be invited to answer online-questionnaires on their cannabis consumption behavior, their mental and physical health. The entire study lasts 2.5 years.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Experimental group | Experimental | Other: Regulated cannabis access in pharmaciesImmediately regulated cannabis access in pharmacies. |
| Control group | No intervention | –During the first six months participants of the control group have to continue to buy their cannabis on the illicit market. Afterthese six months they also have access to regulated cannabis access. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- At least 18 years, residence in Basel-Stadt, consuming cannabis at least monthly during the last 6 months (positive urine sample)
Key exclusion criteria (1 listed)
- pregnant or breastfeeding, currently suicidal, currently psychotic, current inpatient psychiatric treatment
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Regulated cannabis access in pharmaciesThe study does not investigate the health effects of cannabis. The study investigates the effects of regulated cannabis access on cannabis consumption and health in comparison to the unregulated illegal market. | Other | Experimental group |
Primary outcome
Change in problematic cannabis consumption behaviour
Time frame: 6 / 12 /18 /24 / 30 months
Cannabis Use Disorder Identification Test - Revised; min. value 0, max. value 32; higher scores mean worse outcome
4 secondary outcomes
Change in depression
Time frame: 6 / 12 /18 /24 / 30 months
Change in anxiety
Time frame: 6 / 12 /18 /24 / 30months
Change in psychosis
Time frame: 6 / 12 /18 /24 / 30 months
Change in physical health
Time frame: 6 / 12 /18 /24 / 30 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Sep 2026.
- Derived from this study: PubMed 37032954Baltes-Flueckiger L, Steinauer R, Meyer M, Vogel M, Walter M. Effects of cannabis regulation in Switzerland: Study protocol of a randomized controlled trial. Front Psychiatry. 2023 Mar 23;14:1139325. doi: 10.3389/fpsyt.2023.1139325. eCollection 2023.
- Individual participant dataSharing planned: Yes. All IPD that underlie results in publications.
Related trials for Cannabis Use Disorder
Active, not recruitingObservational study
Cannabis Use and Outcomes in Black and White Patients With Cancer
Cancer
Recruiting
MATAspire: Mental Health Awareness Tailored App for Substance Prevention and Integrated Resilience Education
Alcohol Use, Cannabis Use
RecruitingObservational study
Study of an Oral Fluid Testing Approach
Cannabis Use, Cannabis Intoxication
Not yet recruitingEarly Phase 1
Research Investigating Drug Effects-2 (RiDE-2)
Cannabis Use, Substance Use Disorder (SUD)
Active, not recruiting
Evaluation of a Brief Computerized and Smart Phone-based Intervention for Stress in Regular Cannabis Users
Cannabis Use Disorder
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Regulated cannabis access in pharmacies in people with Cannabis Use Disorder and Mental Health Disorder, run by Health Department of the Canton of Basel-Stadt at 1 site in Switzerland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 2 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in problematic cannabis consumption behaviour (time frame: 6 / 12 /18 /24 / 30 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05522205, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Sep 2026.